Peripheral/Endo

Reflow Medical Completes DEEPER LIMUS Clinical Trial Enrollment

SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Reflow Medical, Inc., a California-based medical device company, has completed enrollment in the DEEPER LIMUS clinical trial (NCT04162418) to evaluate the Temporary Spur Stent System, a patented device designed to treat long, diffuse and severely calcified infrapopliteal disease. The system allows for uniform expansion of the stent […]

Humacyte Announces JAMA Surgery Publication Highlighting Potential of Human Acellular Vessel™ (HAV™) to Expand Vascular Trauma Reconstruction and Bypass Treatment Options

— HAV implanted in nearly 500 patients with more than 1,000 patient-years of follow up to date, for treatment of peripheral arterial disease, arteriovenous access for hemodialysis, and trauma – — Immediately-available HAV, if approved, would represent significant and innovative advancements for vascular repair and replacement conduits– DURHAM, N.C., June 29, […]

A Randomized MRI-Based Study Reveals VasQ™ External Support Promotes More Stable Hemodynamics than Standard AVFs

TEL AVIV, Israel, June 28, 2022 /PRNewswire/ — Dr. Andrea Remuzzi and his research team at The University of Bergamo have recently published a randomized-controlled MRI-based computational fluid dynamic study in the Journal of Vascular Access that revealed the impact of VasQ™ External Support on fistula morphology and flow. VasQ, a Laminate Medical Technologies device is implanted […]

Endologix Reports 12 Month Data from DETOUR 2 Clinical Trial at 2022 Vascular Annual Meeting

The DETOUR 2 study is a prospective, single-arm, international, multi-center clinical evaluation of the novel DETOUR™ System for fully percutaneous femoropopliteal bypass procedures. IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held global medical device company dedicated to improving patients’ lives with innovative interventional treatments for vascular disease, recently announced the 12-month […]

VasQ™ External Support Comparative U.S. Study Demonstrated Greater Fistula Primary Patency and Usability with a Lower Intervention Rate

CHARLESTON, S.C., June 21, 2022 /PRNewswire/ — The U.S. VasQ™ External Support Comparative Study results were presented this month for the first time globally at the VASA 2022. The study was a propensity-score matched comparison of the VasQ U.S. Pivotal Study single-arm prospective data with untreated contemporary Medicare patients who underwent arterio-venous fistula […]

Humacyte Provides Update on Patients Treated at Front-Line Hospitals in Ukraine with the Human Acellular Vessel™ (HAV™) for Repair of Vascular Trauma Injuries

— Successful first two HAV implantations in wounded Ukrainian citizens — HAVs were provided under Humacyte’s initiative to assist Ukraine humanitarian medical effort — Provides further real-world evidence of the potential of HAV treatment for trauma DURHAM, N.C., June 21, 2022 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage […]

Cordis Announces Successful First-in-Human Use of the Radianz Radial Peripheral System™

Successful procedures initiate U.S. limited market release MIAMI LAKES, Fla., June 16, 2022 /PRNewswire/ — Cordis, a global leader in cardiovascular technologies, today announced the first-in-human use of the Radianz Radial Peripheral System™ by Jihad Mustapha, MD, FACC, FSCAI at Advanced Cardiac & Vascular Centers (ACV) in Grand Rapids, Michigan. The Radianz Radial Peripheral System™ solution […]

FLEX Vessel Prep AV Registry Data Shows A Longer Lasting Solution to Stand Alone PTA When Treating AV Access Fistulas and Grafts

MINNEAPOLIS, June 15, 2022 /PRNewswire/ — VentureMed Group, Inc., a privately held medical device innovator in access management for arteriovenous (AV) fistulas and grafts and vessel preparation for interventional treatment of peripheral arterial disease (PAD) announced data presented at the Vascular Access Societies of the Americas (VASA) June 9-11, Charleston, South Carolina. Study Details and FindingsFLEX Vessel […]

Silk Road Medical Announces Post Approval Study for the Treatment of Standard Surgical Risk Patients using TCAR

SUNNYVALE, Calif., June 15, 2022 (GLOBE NEWSWIRE) —  Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced a prospective study to evaluate the TCAR® system in the treatment of standard surgical risk patients with carotid artery disease. The post-market […]